Dr. Gillinov is the co-author with Dr. Steven Nissen, Chairman of Cardiovascular Medicine of the book, Heart 411: The Only Book on Heart Health You'll Ever Need which will be published in February, 2012 by Crown Archetype.
Cardiologist Steve Nissen described DEFINE as a medium-sized safety trial intended to find out "whether anacetrapib would show the same increase in adverse cardiovascular events that was seen with torcetrapib."
The lipoprotein enhanced the ability of HDL, or “good” cholesterol to usher fat out of the arteries and into the liver for excretion leading to the purchase of Esperion Therapeutics, the tiny company that had produced recombinant Apo-A1 Milano, by Pfizer for $1.3 billion.
•
Starting with linked COX-2 inhibitors, such as Vioxx (rofecoxib) in 2001, Nissen was one of the first physicians to link it to an increased risk of heart attacks and strokes.
Steven Spielberg | Steven Seagal | Steven Soderbergh | Steven Holl | Steven Tyler | Steven Isserlis | Steven Gerrard | Steven Curtis Chapman | Steven Berkoff | Steven Wilson | Steven Pinker | Steven Levy | Steven Moffat | Steven 'Bo' Keeley | Steven Weinberg | Steven Meisel | Steven Hyde | Steven Ford | Steven Stucky | Steven Dann | Steven | Steven Yeun | Steven Webber | Steven T. Seagle | Steven R. Smith | Steven Houghton | Steven Hirsch | Steven Heighton | Steven Dietz | Steven Chu |
A 2011 study by Dr. Diana Zuckerman and Paul Brown of the National Research Center for Women and Families, and Dr. Steven Nissen of the Cleveland Clinic, published in the Archives of Internal Medicine, showed that most medical devices recalled in the last five years for “serious health problems or death” had been previously approved by the FDA using the less stringent, and cheaper, 510(k) process.